MONITORING THE CELLULAR COMPONENTS OF THE IMMUNE SYSTEM DURING CLINICAL TRIALS: A TRANSLATIONAL MEDICINE APPROACH - Flow Cytometry in Drug Discovery and Development - page 198

inflamed kidneys and urine and provide a new biomarker for acute nephritis flares in SLE
patients. Arthritis Rheum. 2009;60(1):199-206.
25. Henneken M, Dorner T, Burmester GR, Berek C. Differential expression of chemokine
receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic
lupus erythematosus. Arthritis Res. Ther. 2005;7:R1001.
26. Souto-Carneiro MM, Mahadevan V, Takada K, Fritsch-Stork R, Nanki T, Brown M,
Fleisher TA, Wilson M, Goldbach-Mansky R, Lipsky PE. Alterations in peripheral blood
memory B cells in patients with active rheumatoid arthritis are dependent on the action of
tumour necrosis factor. Arthritis Res. Ther. 2009;11:R84.
27. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic
agents. J. Am. Acad. Dermatol. 2002;46:1-23.
28. LewW, BowcockAM, Krueger JG. Psoriasis vulgaris: cutaneous lymphoid tissue supports
T-cell activation and type 1 inflammatory gene expression. Trends Immunol. 2004;25

(6):295-305.
29. Chamian F, Lin SL, Lee E, Kikuchi T, Gilleaudeau P, Sullivan-Whalen M, Cardinale I,
Khatcherian A, Novitskaya I, Wittkowski KM, Krueger JG, Lowes MA. Alefacept (anti-
CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative
preservation of central memory T cells (Tcm) in psoriasis. J. Transl. Med. 2007;5:27.
30. Lawson JM, Tremble J, Dayan C, Beyan H, Leslie RDG, PeakmanM, Tree TIM. Increased
resistance to CD4 þ CD25hi regulatory T cell-mediated suppression in patients with type 1
diabetes. Clin. Exp. Immunol. 2008;154:353-359.
31. Ward JR, Wilson HL, Francis SE, Crossman DC, Sabroe I. Translational mini-review
series on immunology of vascular disease: inflammation, infections and Toll-like receptors
in cardiovascular disease. Clin. Exp. Immunol. 2009;156:386-394.
32. Abdwani R, Mani R. Anti-CD20monoclonal antibody in acute life threatening haemolytic
anaemia complicating childhood onset SLE. Lupus 2008;18:460-464.
33. Reynolds JA, Toescu1 V, Yee1 CS, Prabu1 A, Situnayake D, Gordon C. Effects of
rituximab on resistant SLE disease including lung involvement. Lupus 2009;18:67-73.
34. Dass S, Rawstron AC, Vital EM, Henshaw K, McGonagle D, Emery P. Highly sensitive B
cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis
Rheumat. 2008;58(10):2993-2999.
35. Lee JW, Devanarayan V, Barrett YC, Weiner R, Allinson J, Fountain S, Keller S,Weinryb I,
Green M, Duan L, Rogers JA, MillhamR, O'Brien PJ, Sailstad J, Khan M, Ray C, Wagner
JA. Fit-for-purpose method development and validation for successful biomarker
measurement. Pharm. Res. 2006;23(2).
36. Appay V, van Lier RAW, Sallusto F, Roederer M. Phenotype and function of human T
lymphocyte subsets: consensus and issues. Cytometry A 2008;73(11):975-983.